Subjects taking warfarin should be monitored regularly for changes in prothrombin time or international normalized ratio (INR)
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history
Prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)
Prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)
International normalized ratio (INR) or prothrombin time (PT) INR ?1.5 × institutional ULN or PT ?5 seconds above institutional ULN
Prothrombin time (PT)/international normalized ratio and (PTT) in normal range ± 25%
International normalized ratio/prothrombin time ? 1.5 x upper limit or normal
Prothrombin time (PT) or international normalize rate (INR) within 1.5x upper limit of normal;
Prothrombin time international normalized ratio (INR) =< 2
Prothrombin (PT) - international normalized ratio (INR) < 1.5
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULN, obtained =< 14 days prior to registration
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x institutional upper limit of normal (or an in-range INR, usually between 2 and 3 if a patient is on a stable dose of therapeutic warfarin)
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN
Prothrombin time (PT) within 2 seconds of the upper limit of normal (institutional normal ratio [INR] =< 1.8)
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN
PT (Prothrombin time) and/or international normalized ratio (INR) =< 1.5 x ULN
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin) (obtained within 28 days prior to first study treatment)
Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)
Obtained =< 14 days prior to registration: Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
Prothrombin time/international normalized ratio (PT INR) < 1.4
Prothrombin time (PT) and international normalized ratio (INR) =< 1.5 x ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 2.3 or PT =< 6 seconds above control (within 14 days prior to registration)\r\n* NOTE: Abnormal PT/INR may be considered, with documented principal investigator (PI) approval, if it is due to the use of anticoagulants; for such patients, a normal PT/INR must be available from before the start of anticoagulation treatment\r\n* NOTE: Performed at time of screening angiogram; can be outside 14 days if applicable
Prothrombin time with international normalized ratio (INR) =< ULN for the laboratory
International normalized ratio (INR) < IULN or prothrombin time (PT) < IULN
International normalized ratio (INR) =< IULN or prothrombin time (PT) =< IULN
Prothrombin time/international normalized ratio (PT/INR) < 1.4 for patients not on warfarin
Prothrombin time (PT)/international normalization ratio (INR) < 1.5 x ULN
Within 3 months of registration: International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)
Prothrombin time or international normalized ratio (INR) =< 1.5 X upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) < 1.7 unless using warfarin for therapeutic anti-coagulation
Prothrombin time (PT) and international normalized ratio (INR) < 1.2 x ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN (except for patients on anticoagulation)
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN)
International normalized ratio (INR) or prothrombin time (PT) < 1.5 x ULN
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless the patient is receiving anticoagulant therapy
Prothrombin time (PT)/international normalized ratio (INR) =< 1.2 x ULN
Evidence of a bleeding diathesis, coagulopathy or prothrombin time (PT) international normalized ratio (INR) > 1.5
International normalized ratio (INR)/prothrombin time (PT) =< 1.5 obtained =< 14 days prior to registration
Coagulation: Prothrombin Time (PT) > 4 seconds more than the ULN or International Normalized Ratio (INR) > 1.7
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN within 14 days prior to randomization; for laboratories that do not report an ULN for the INR assay, use =< 1.5 as the value for the ULN; patients receiving therapeutic anti-coagulants are not eligible
PT/international normalized ratio (INR) ?ULN; aPTT ?ULN.
International normalization ratio (INR) or prothrombin time (PT) ? 1.5 x
International normalized ratio =< 1.5 and activated prothrombin time =< 1.5 x ULN for patients not receiving anti?coagulation therapy
Prothrombin time (PT)/international normalized ratio (INR) within normal limits (+/- 15%) or within therapeutic range if on warfarin
Patients with prothrombin time (PT) and/or international normalized ratio (INR) higher than or equal to 1.5 time upper limit of normal, unless patients have lupus anticoagulant in which case they are eligible if cleared by hematology
Obtained within 30 days prior to registration: International normalized ratio (INR) or prothrombin time (PT) =< 2 x ULN (Note: use of vitamin K antagonist is not allowed)
Cohort 2 (MTD) only: prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN
Prothrombin time (PT)/international normalized ratio (INR) within institutional normal limits
Prothrombin time (PT)/international normalized ratio (INR) < 1.25 x ULN (Cohort II [MTD] only)
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN
International normalized ratio (INR) =< 1.5 x ULN or prothrombin time (PT) =< 1.5 x ULN seconds above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosis
Prothrombin time (PT), international normalized ratio (INR) less than 1.5 times the institutional upper limit of normal
Prothrombin time (PT), international normalized ratio (INR) =< 1.5 x institutional ULN unless patient is therapeutically anticoagulated; if on anticoagulants, PT/INR need to be within appropriate anticoagulation limits for the clinical indication; patients who are receiving anticoagulants may participate in the trial if their anticoagulation can be stopped safely for several days at the time of each biopsy
Prothrombin time (PT)/international normalized ratio (INR) monitoring, < 1.5 x institutional upper limits of normal
Prothrombin time (PT)/international normalized ratio (INR) must be =< 1.2 x the laboratory ULN
Prothrombin time (PT) within 2 seconds of the upper limit of normal (international normalized ratio [INR] =< 1.8)
Adequate coagulation defined as\r\n* International normalized ratio (INR)/prothrombin time (PT) =< 1.5 x upper limit of normal
Prothrombin time (PT)/international normalized ratio (INR) =< 2.3 or PT =< 6 seconds above control; if subjects are being anticoagulated they can participate if proof of no coagulation abnormality existed prior to use of anticoagulants
Prothrombin time (PT) =< 26 seconds or international normalized ratio (INR) =< 2.5
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN) (if not receiving anticoagulation therapy)
INR ? 2.3 or Prothrombin time (PT) ? 6 seconds above control;
Prothrombin Time - International Normalized Ratio (PT-INR)
International Normalized Ratio (INR) or Prothrombin Time (PT) ?1.5 X ULN
Prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to study registration
Prothrombin time international normalized ratio (INR) =< 2; AND
International normalized ratio 1.5 × ULN or prothrombin time 5 seconds above ULN.
Prothrombin time (PT) such that international normalized ratio (INR) is less than or equal to 1.3 x upper limit of normal (ULN)
Adequate prothrombin time/international normalized ratio (PT/INR) < 1.4 for patients not on warfarin confirmed by testing within 21 days prior to study registration
Patients must have normal coagulation studies (prothrombin time [PT]/international normalized ratio [INR] < 1.5 times ULN) within 14 days prior to the initiation of study treatment
Prothrombin time (PT)/international normalized ratio (INR) < 1.5 times upper limit of normal within 14 days before enrollment
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 times upper limit of normal (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)
Prothrombin time (PT)-international normalized ratio (INR) =< 2.3 or PT =< 6 seconds above control
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN)
Concurrent treatment with warfarin (Coumadin) is allowed, but close monitoring of the prothrombin time (PT)/international normalized ratio (INR) is recommended
Maximum Child-Pugh score of 5 (NOTE: this requires prothrombin time [PT] or international normalized ratio [INR] measurement at baseline)
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for the management of venous thrombosis including pulmonary embolus)
Patients on stable anticoagulation are eligible for enrollment; for patients on warfarin, prothrombin time (PT)/international normalized ratio (INR) should be monitored every 2 weeks during induction therapy, monthly thereafter, or more frequent as clinically indicated
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)
Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x ULN
Prothrombin time (PT) or international normalized ratio (INR) =< 1.5 X institutional upper limit of normal (ULN) unless patients are on therapeutic anticoagulation with warfarin
EXPANSION COHORT ONLY: Prothrombin time (PT) or international normalized ratio (INR) =< 2 X institutional upper limit of normal (ULN) unless patients are on therapeutic anticoagulation with warfarin
Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulation
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
Prothrombin time (PT) or International Normalized Ratio (INR) ? 1.25 x ULN; for patients with hepatocellular carcinoma only, INR <1.7 or prothrombin time (PT) or < 4 seconds above ULN (i.e. Child-Pugh Score is no greater than 1 for the coagulation parameter); for patients with hepatocellular carcinoma only, serum albumin > 2.8 g/dL (i.e. Child-Pugh Score for albumin is no greater than 2). For the hematologic malignancy patients, the coagulation and albumin status cited above do not apply
Patient has acceptable coagulation status; for patients not receiving anticoagulation: international normalized ratio of a measure of prothrombin time =< 1.3
International normalized ratio (INR) >2.3 or prothrombin time (PT) >6 seconds above control
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
TPI 287 may interfere with coumadin dosing and patients who are taking this combination will require monitoring of their PT, PTT and international normalized ratio (INR).
Prothrombin time (PT) with international normalized ratio (INR) ?1.5
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN
Prothrombin time/international normalized ratio (PT INR) < 1.4
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolism)
Evidence of active bleeding, a bleeding diathesis or prothrombin time (PT) international normalized ratio (INR) > 1.5
Prothrombin time International Normalized Ratio (INR) > 1.5
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
Prothrombin time (PT) and/or international normalized ratio (INR) ? 1.3 × the upper limit of normal (ULN)
Prothrombin time (PT) such that international normalized ratio (INR) is < 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)
International normalized ratio (INR) or prothrombin time (PT) within normal institutional limits
Obtained within 28 days prior to registration: International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)
Patients should have international normalized ratio (INR) =< 1.4 and prothrombin time (PT) =< 40 seconds (unless due to lupus anticoagulant); in patients not meeting these parameters, clearance by hematology will be required prior to undergoing a biopsy
Complete blood count (CBC), chemistry panel (CMP) and coagulation panel (prothrombin time [PT] & international normalized ratio [INR]) no greater than 4 weeks prior to registration